The daily business briefing: May 17, 2022

The FDA, Abbott agree to speed reopening of baby formula plant, Musk says Twitter deal can't move forward without fake-account data, and more

Baby formula
(Image credit: Ting Shen/Bloomberg/Getty Images)

1. FDA, Abbott reach agreement to reopen baby formula plant

The Food and Drug Administration and Abbott Nutrition reached an agreement Monday aiming to help speed up the reopening of the company's shuttered baby formula plant. The FDA said Abbott might be able to resume production at the Sturgis, Michigan, facility in two weeks. The factory has been shut down since February, when a potentially deadly bacteria was detected on equipment following illnesses and two deaths among babies who consumed formula produced there. The reopening deal is part of an effort to ease a nationwide shortage of baby formula that is stoking alarm and hardship for parents. The FDA said Monday it would make it easier to import some infant formulas from abroad.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Harold Maass, The Week US

Harold Maass is a contributing editor at The Week. He has been writing for The Week since the 2001 debut of the U.S. print edition and served as editor of TheWeek.com when it launched in 2008. Harold started his career as a newspaper reporter in South Florida and Haiti. He has previously worked for a variety of news outlets, including The Miami Herald, ABC News and Fox News, and for several years wrote a daily roundup of financial news for The Week and Yahoo Finance.